What were Sai Life Sciences Ltd's latest quarterly results?
Sai Life Sciences Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: +85.2% (stable)
- Revenue Growth YoY: +26.4%
- Operating Margin: 34.0% (volatile)
Sai Life Sciences Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +17.3%AverageNew This Week
In Week of Apr 3, 2026, Sai Life Sciences Ltd (Pharma - API & CRAMS) is outperforming Nifty 500 with +17.3% relative strength. Fundamentals: Average.
Emerging Opportunity
What's Happening
⏳Steady earner with flat PE — waiting for re-rate catalyst
🌐FII stake increased 10.1% this quarter
🏛️DII accumulation — stake up 16.7%
💰Trading 48% above estimated fair value — significant premium
Key Numbers
PAT Growth YoY
+85%
Stable
Revenue YoY
+26%
Stable
Operating Margin
34.0%
+700 bps YoY
PE Ratio
61.6
Current Price
₹986
Fundamental Score
43/100
Average
3Y PAT CAGR
+80%
Market Cap
20.3K Cr
Valuation
Significantly Overvalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
How Fast Is Sai Life Sciences Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +26% | +25% | Stable |
| PAT (Net Profit) | +85% | +80% | Stable |
| OPM | 34.0% | +700 bps | Volatile |
Other Top Pharma - API & CRAMS Stocks Beating Nifty 500
Frequently Asked Questions: Sai Life Sciences Ltd
Based on publicly available financial data. This is educational research, not investment advice.
Is Sai Life Sciences Ltd's profit growing or declining?
Sai Life Sciences Ltd's profit is growing with an stable trend.
- PAT Growth YoY: +85.2% (latest quarter)
- PAT Growth QoQ: +19.0% (sequential)
- 3-Year PAT CAGR: +80.0%
- Trend: Stable — consistent growth pattern
What is Sai Life Sciences Ltd's revenue growth trend?
Sai Life Sciences Ltd's revenue growth trend is stable.
- Revenue Growth YoY: +26.4%
- Revenue Growth QoQ: +3.5% (sequential)
- 3-Year Revenue CAGR: +24.9%
How is Sai Life Sciences Ltd's operating margin trending?
Sai Life Sciences Ltd's operating margin is volatile.
- Current OPM: 34.0%
- OPM Change YoY: +7.0% basis points
- OPM Change QoQ: +7.0% basis points
What is Sai Life Sciences Ltd's 3-year profit and revenue CAGR?
Sai Life Sciences Ltd's long-term compounding rates
- 3-Year Profit CAGR: +80.0%
- 3-Year Revenue CAGR: +24.9%
Is Sai Life Sciences Ltd's growth accelerating or decelerating?
Sai Life Sciences Ltd's earnings growth is stable with mixed signals on a sequential basis.
- YoY Acceleration: -14.8% bps
- Sequential Acceleration: -21.0% bps
What is Sai Life Sciences Ltd's trailing twelve month (TTM) performance?
Sai Life Sciences Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹332 Cr
- TTM PAT Growth: +100.0% YoY
- TTM Revenue: ₹2,000 Cr
- TTM Revenue Growth: +39.5% YoY
- TTM Operating Margin: 28.1%
Is Sai Life Sciences Ltd overvalued or undervalued?
Sai Life Sciences Ltd appears significantly overvalued based on our fair value analysis.
- Valuation Signal: Significantly Overvalued
- Current PE: 61.6x
- Price-to-Book: 9.2x
What is Sai Life Sciences Ltd's current PE ratio?
Sai Life Sciences Ltd's current PE ratio is 61.6x.
- Current PE: 61.6x
- Market Cap: 20.9K Cr
How does Sai Life Sciences Ltd's valuation compare to its history?
Sai Life Sciences Ltd's current PE is 61.6x.
- Current PE: 61.6x
- Valuation Assessment: Significantly Overvalued
What is Sai Life Sciences Ltd's price-to-book ratio?
Sai Life Sciences Ltd's price-to-book ratio is 9.2x.
- Price-to-Book (P/B): 9.2x
- Book Value per Share: ₹107
- Current Price: ₹986
Is Sai Life Sciences Ltd a fundamentally strong company?
Sai Life Sciences Ltd is rated Average with a fundamental score of 43.27/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +26.4% (10% weight)
- PAT Growth YoY: +85.2% (10% weight)
- PAT Growth QoQ: +19.0% (10% weight)
- Margins stable (10% weight)
Is Sai Life Sciences Ltd debt free?
Sai Life Sciences Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹352 Cr
What is Sai Life Sciences Ltd's return on equity (ROE) and ROCE?
Sai Life Sciences Ltd's return ratios over recent years
- FY2023: ROCE 6.0%
- FY2024: ROCE 11.0%
- FY2025: ROCE 14.0%
Is Sai Life Sciences Ltd's cash flow positive?
Sai Life Sciences Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹314 Cr
- Free Cash Flow (FCF): ₹-222 Cr
- CFO/PAT Ratio: 185% (strong cash conversion)
What is Sai Life Sciences Ltd's dividend yield?
Sai Life Sciences Ltd currently does not pay a significant dividend (yield 0.00%).
- Dividend Yield: 0.00%
- Current Price: ₹986
Who holds Sai Life Sciences Ltd shares — promoters, FII, DII?
Sai Life Sciences Ltd's shareholding pattern (Dec 2025)
- Promoters: 34.7%
- FII (Foreign): 21.4%
- DII (Domestic): 31.4%
- Public: 12.5%
Is promoter holding increasing or decreasing in Sai Life Sciences Ltd?
Sai Life Sciences Ltd's promoter holding has decreased recently.
- Current Promoter Holding: 34.7% (Dec 2025)
- Previous Quarter: 35.0% (Sep 2025)
- Change: -0.25% (decreasing — worth monitoring)
How long has Sai Life Sciences Ltd been outperforming Nifty 500?
Sai Life Sciences Ltd has been outperforming Nifty 500 for 1 consecutive week, indicating early-stage outperformance.
Is Sai Life Sciences Ltd a new momentum entry or an established outperformer?
Sai Life Sciences Ltd is a new entry this week — it just started outperforming Nifty 500. New entries are worth monitoring for follow-through.
Is Sai Life Sciences Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Sai Life Sciences Ltd may be worth studying
- Earnings growing at +85.2% YoY
- Cash flow is positive — CFO ₹314 Cr
What is the investment thesis for Sai Life Sciences Ltd?
Sai Life Sciences Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +26.4% YoY
Risk Factors (Bear Case)
- Appears significantly overvalued
What is the future outlook for Sai Life Sciences Ltd?
Sai Life Sciences Ltd's forward outlook based on current data signals
- Earnings Trend: stable
- Revenue Trend: stable
- Margin Trend: volatile
- Valuation: Significantly Overvalued
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.